Evidence map›Paper›PMID 40128545›Full record

ArticleNature communications2025

Author Correction: Pan-cancer multi-omic model of LINE-1 activity reveals locus heterogeneity of retrotransposition efficiency.

Alexander Solovyov, Julie M Behr, David Hoyos, Eric Banks, Alexander W Drong, Bryan Thornlow, Jimmy Z Zhong, Enrique Garcia-Rivera, Wilson McKerrow, Chong Chu and 6 more

Abstract readPublished Erratum
PubMed Full text at PMC Publisher
In one paragraph

Article in Nature communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

16 authors.

Alexander Solovyov *Halvorsen Center for Computational Oncology, Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA. solovyova@mskcc.org.
Julie M Behr *ROME Therapeutics, Inc., Boston, MA, USA.ORCID http://orcid.org/0000-0001-8601-4902
David HoyosHalvorsen Center for Computational Oncology, Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Eric BanksROME Therapeutics, Inc., Boston, MA, USA.
Alexander W DrongROME Therapeutics, Inc., Boston, MA, USA.
Bryan ThornlowROME Therapeutics, Inc., Boston, MA, USA.
Jimmy Z ZhongROME Therapeutics, Inc., Boston, MA, USA.
Enrique Garcia-RiveraROME Therapeutics, Inc., Boston, MA, USA.
Wilson McKerrowROME Therapeutics, Inc., Boston, MA, USA.
Chong ChuROME Therapeutics, Inc., Boston, MA, USA.ORCID http://orcid.org/0000-0002-0796-2339
Cedric ArisdakessianROME Therapeutics, Inc., Boston, MA, USA.ORCID http://orcid.org/0000-0001-5255-0942
Dennis M ZallerROME Therapeutics, Inc., Boston, MA, USA.
Junne KamiharaDivision of Hematology/Oncology, Boston Children's Hospital, Boston, MA, USA.ORCID http://orcid.org/0000-0002-2852-7387
Liyang DiaoROME Therapeutics, Inc., Boston, MA, USA.
Menachem FromerROME Therapeutics, Inc., Boston, MA, USA.ORCID http://orcid.org/0000-0003-3749-4342
Benjamin D GreenbaumHalvorsen Center for Computational Oncology, Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA. greenbab@mskcc.org.ORCID http://orcid.org/0000-0001-6153-8793

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID40128545
PMCPMC11933348

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.